Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF)

  • Tina Smets
  • Frederik Stevenaert
  • Homer AdamsIII
  • Greet VanhoofEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1792)


Mass cytometry has emerged as a new state-of-the-art technology that enables in-depth characterization of cellular populations and functions at a single cell resolution. We describe the application of this technology to deeply phenotype the blood and bone marrow components of multiple myeloma patients in a clinical setting. This technology allows for simultaneous quantification of more than 40 markers, overcoming the challenges of traditional fluorescence-based flow cytometry.

Key words

Mass cytometry CyTOF Multiple myeloma Immunophenotyping Single cell Barcoding Smart tube Peripheral blood Bone marrow 



The authors would like to thank Christoph Heuck for his suggestions and critical reading of the manuscript.


  1. 1.
    Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK (2012) A deep profiler’s guide to cytometry. Trends Immunol 33(7):323–332. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Spitzer MH, Nolan GP (2016) Mass Cytometry: single cells, many features. Cell 165(4):780–791. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219. CrossRefPubMedGoogle Scholar
  4. 4.
    Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551–1560. CrossRefPubMedGoogle Scholar
  5. 5.
    Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG (2016) Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 128(14):1821–1828. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Adams H, Stevenaert F, Krejcik J, Van der Borght K, Casneuf T, Smets T, Bald J, Abraham Y, Ceulemans H, Vanhoof G, Ahmadi T, Usmani SZ, Plesner T, Lonial S, van Kessel-Welmers B, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK (2016) High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism of action. Blood 128(22):4521Google Scholar
  7. 7.
    Qiu P, Simonds EF, Bendall SC, Gibbs KD Jr, Bruggner RV, Linderman MD, Sachs K, Nolan GP, Plevritis SK (2011) Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol 29(10):886–891. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Tina Smets
    • 1
  • Frederik Stevenaert
    • 1
  • Homer AdamsIII
    • 2
  • Greet Vanhoof
    • 1
    Email author
  1. 1.Janssen Research and DevelopmentBeerseBelgium
  2. 2.Janssen Research and Development, LLCSpring HouseUSA

Personalised recommendations